Regulatory and Reimbursement Issues in Biomarkers

To get the inclusion and repayment remained an essential obstacle towards the appropriation of new Biomarker testicles for d3edliest illnesses like malignant growth. On the off chance that specific tests are not acknowledged by the administrative bodies, and insurance agencies, it profoundly impacts the contestant of new Biomarker tests. The Centers for Medicare and Medicaid Services distinguished just 65 tests under the repayment classification. Any test past that albeit valuable may not repay consequently makes an immense test. 

  • Policy issues in the development of Personalized Medicine
  • coverage and reimbursement issues in Cancer biomarkers
  • Identification of molecular Biomarkers of clinical utility
  • Ethical, legal and social implications (ELSI) of Biomarkers
  • Policy issues in development and adoption of Biomarkers for Molecularly Targeted Cancer Therapies
  • Challenges and Issues in Biomarkers development

Related Conference of Regulatory and Reimbursement Issues in Biomarkers

March 18-19, 2024

5th Global Summit on Oncology and Hematology

Zurich, Switzerland
June 10-11, 2024

8th Global Meeting on Oncology and Radiology

Barcelona, Spain
July 11-12, 2024

24th World Congress on Cancer and Diagnostics

Vancouver, Canada
July 18-19, 2024

14th World Congress on Breast Cancer

Paris, France
September 19-20, 2024

25th World Congress on Cancer Summit

Paris, France

Regulatory and Reimbursement Issues in Biomarkers Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in